Nadine Wolgast

Kiel, SH 24105, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.

Nationwide analysis of acute promyelocytic leukemia: incidence and patient outcomes in Germany.

Journal: Haematologica
Published: December 23, 2025

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

Journal: Leukemia
Published: October 22, 2025

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

Journal: HemaSphere
Published: September 30, 2025

Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia.

Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia.

Journal: Blood cancer journal
Published: September 19, 2025

Epidemiology and survival of patients with T-cell prolymphocytic leukemia.

Epidemiology and survival of patients with T-cell prolymphocytic leukemia.

Journal: Blood cancer journal
Published: September 07, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups.

Journal: HemaSphere
Published: August 14, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis.

Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis.

Journal: The Lancet regional health. Europe
Published: May 18, 2025

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Journal: Haematologica
Published: February 06, 2024

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols.

Journal: Leukemia
Published: October 18, 2023

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Journal: Blood
Published: July 05, 2023
Showing 1-12 of 13

Last Updated: 09/26/2026